According to a new study titled Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in multiple rodent models of nicotine dependence, the administration of the cannabis compound THCV (tetrahydrocannabivarin) reduces nicotine cravings and use in rodents.
The study was published by the British Journal of Pharmacology, as well as the U.S. National Institute of Health
For the study researchers at the Virginia Commonwealth University, the Beijing Institute of Pharmacology and Toxicology (China), and the University of Aberdeen (Scotland) assessed the influence of delta-8 THCV in seven different rodent models relevant to nicotine dependence. They reported that the compound significantly “attenuated intravenous nicotine self-administration, and both cue-induced and nicotine-induced relapse to nicotine-seeking behavior in rats [and] also significantly attenuated nicotine-induced conditioned place preference and nicotine withdrawal in mice.”
The study concludes by stating that “Δ8 -THCV may have therapeutic potential for the treatment of nicotine dependence. We also suggest that tetrahydrocannabivarins should be tested for possible anti-addiction efficacy in a broader range of preclinical animal models, against other addictive drugs, and eventually in humans.”
The study’s full abstract can be found below:
BACKGROUND AND PURPOSE:
Both types of cannabinoid receptors – CB1 and CB2 – regulate brain functions relating to addictive